Close

KemPharm (KMPH) Reports Positive Topline Results from KP415 Pharmacokinetic Study in Children and Adolescents With ADHD

March 20, 2018 7:30 AM EDT Send to a Friend
KemPharm, Inc. (NASDAQ: KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today announced that ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login